Physician profile
Daxton Duncan
NPI 1851757983
$30,661.71
in general payments reported to CMS, 2019-2025
26 companies · $16K in 2025
The $16K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,812 · 2022: $8,253 · 2023: $1,374 · 2024: $2,978 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Travel and Lodging: $4,841 · Food and Beverage: $4,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,960.00 |
| Travel and Lodging | $4,840.69 |
| Food and Beverage | $4,796.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $18,447.97 | 2024-2025 | Evoke |
| Abbott Laboratories | $6,166.43 | 2021-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $1,726.42 | 2021-2025 | Intracept, General - Pain Management |
| Relievant Medsystems, INC. | $1,583.90 | 2022-2023 | Intracept |
| Medtronic, INC. | $599.81 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Mml US, INC. | $441.65 | 2022-2025 | Reactiv8 |
| Vertos Medical, INC. | $336.51 | 2022-2024 | Mild Device Kit |
| Amgen INC. | $329.23 | 2021-2023 | Prolia, Evenity |
| Radius Health, INC. | $178.48 | 2021-2025 | Tymlos |
| Arbor Pharmaceuticals, INC. | $102.20 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $89.24 | 2022-2025 | Horizant, Horizant |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.33 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $73.69 | 2024-2025 | |
| Novo Nordisk INC | $72.43 | 2023-2024 | Wegovy, Ozempic, Rybelsus |
| Indivior INC. | $66.96 | 2024-2025 | Sublocade |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $56.26 | 2023-2025 | Belbuca |
| Abbvie INC. | $53.42 | 2023-2024 | |
| Averitas Pharma INC. | $45.21 | 2023 | Qutenza |
| Alexion Pharmaceuticals, INC. | $40.06 | 2023-2025 | Strensiq |
| Ibsa Pharma INC. | $38.14 | 2022-2023 | Tirosint, Licart |
| Lundbeck LLC | $34.38 | 2023-2024 | Vyepti, Rexulti |
| Ironshore Pharmaceuticals INC. | $29.43 | 2023-2024 | Jornay Pm |
| Gilead Sciences, INC. | $23.24 | 2024 | |
| Si-Bone, INC. | $18.52 | 2021 | |
| Axsome Therapeutics, INC. | $16.50 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daxton Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.